Sheng-Ming Deng1, Wei Zhang1, Bin Zhang1, Yi-Wei Wu1. 1. 1 Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou 215000, China ; 2 School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou 215000, China ; 3 Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214000, China.
Abstract
PURPOSE: To determine the diagnostic performance of 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography/computed tomography (FLT PET/CT) and FLT PET for evaluating response to chemotherapy in patients with breast cancer. METHODS: Databases such as PubMed (MEDLINE included) and excerpta medica database (EMBASE), were searched for relevant original articles. The included studies were assessed for methodological quality with quality assessment of diagnosis accuracy studies (QUADAS) score tool. Histopathological analysis and/or clinical and/or radiological follow-up for at least 6 months were used as the reference standard. The data were extracted by two reviewers independently to analyze the sensitivity, specificity, summary receiver operating characteristic (SROC) curve, area under the curve (AUC), and heterogeneity. RESULTS: The present study analyzed a total of 4 selected articles. The pool sensitivity was 0.773 [95% confidence interval (CI): 0.594-0.900]. The pooled specificity was 0.685 (95% CI: 0.479-0.849) on basis of FEM. The pooled LR+, LR-, and DOR were 2.874 (1.492-5.538), 0.293 (0.146-0.589), and 14.891 (3.238-68.475), respectively. The AUC was 0.8636 (±0.0655), and the Q* index was 0.7942 (±0.0636). CONCLUSIONS: Our results indicate that (18)F-FLT PET/CT or PET is useful to predict chemotherapy response in breast cancer with reasonable sensitivity, specificity and DOR. However, future larger scale clinical trials will be needed to assess the regimen of (18)F-FLT PET/CT or PET in monitoring the response to chemotherapy in breast cancer patients.
PURPOSE: To determine the diagnostic performance of 3'-deoxy-3'-(18)F-fluorothymidine positron emission tomography/computed tomography (FLT PET/CT) and FLT PET for evaluating response to chemotherapy in patients with breast cancer. METHODS: Databases such as PubMed (MEDLINE included) and excerpta medica database (EMBASE), were searched for relevant original articles. The included studies were assessed for methodological quality with quality assessment of diagnosis accuracy studies (QUADAS) score tool. Histopathological analysis and/or clinical and/or radiological follow-up for at least 6 months were used as the reference standard. The data were extracted by two reviewers independently to analyze the sensitivity, specificity, summary receiver operating characteristic (SROC) curve, area under the curve (AUC), and heterogeneity. RESULTS: The present study analyzed a total of 4 selected articles. The pool sensitivity was 0.773 [95% confidence interval (CI): 0.594-0.900]. The pooled specificity was 0.685 (95% CI: 0.479-0.849) on basis of FEM. The pooled LR+, LR-, and DOR were 2.874 (1.492-5.538), 0.293 (0.146-0.589), and 14.891 (3.238-68.475), respectively. The AUC was 0.8636 (±0.0655), and the Q* index was 0.7942 (±0.0636). CONCLUSIONS: Our results indicate that (18)F-FLT PET/CT or PET is useful to predict chemotherapy response in breast cancer with reasonable sensitivity, specificity and DOR. However, future larger scale clinical trials will be needed to assess the regimen of (18)F-FLT PET/CT or PET in monitoring the response to chemotherapy in breast cancerpatients.
Entities:
Keywords:
18F-FLT PET; Breast cancer; chemotherapy; meta-analysis
Authors: Seung Jin Lee; Seog Young Kim; Jin Hwa Chung; Seung Jun Oh; Jin Sook Ryu; Yong Sang Hong; Tae Won Kim; Dae Hyuk Moon Journal: Biochem Pharmacol Date: 2010-08-17 Impact factor: 5.858
Authors: Betty S Pio; Cecilia K Park; Richard Pietras; Wei-Ann Hsueh; Nagichettiar Satyamurthy; Mark D Pegram; Johannes Czernin; Michael E Phelps; Daniel H S Silverman Journal: Mol Imaging Biol Date: 2006 Jan-Feb Impact factor: 3.488
Authors: Kaiyumars B Contractor; Laura M Kenny; Justin Stebbing; Lula Rosso; Rizvana Ahmad; Jimmy Jacob; Amarnath Challapalli; Federico Turkheimer; Adil Al-Nahhas; Rohini Sharma; R Charles Coombes; Eric O Aboagye Journal: Clin Cancer Res Date: 2011-10-25 Impact factor: 12.531
Authors: Laura M Kenny; Kaiyumars B Contractor; Justin Stebbing; Adil Al-Nahhas; Carlo Palmieri; Sami Shousha; R Charles Coombes; Eric O Aboagye Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: Laura Kenny; R Charles Coombes; David M Vigushin; Adil Al-Nahhas; Sami Shousha; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2007-03-02 Impact factor: 9.236
Authors: J Dose-Schwarz; R Tiling; S Avril-Sassen; S Mahner; A Lebeau; C Weber; M Schwaiger; F Jänicke; M Untch; N Avril Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640
Authors: Penny F Whiting; Marie E Weswood; Anne W S Rutjes; Johannes B Reitsma; Patrick N M Bossuyt; Jos Kleijnen Journal: BMC Med Res Methodol Date: 2006-03-06 Impact factor: 4.615
Authors: Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen Journal: BMC Med Res Methodol Date: 2003-11-10 Impact factor: 4.615